anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/GB91/01826 Sec. 371 Date May 10, 1993 Sec. 102(e) Date May 10, 1993 PCT Filed Oct. 18, 1991 PCT Pub. No. WO92/07076 PCT Pub. Date Apr. 30, 1992A polypeptide is provided which is capable of binding human TNF alpha  and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF alpha . The ability of the polypeptide to bind TNF alpha  means that it can be used for treating diseases mediated by TNF alpha  activity, such as rheumatoid arthritis.
Participants will be randomized based on Visit 1 FeNO levels (\< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed rescue therapy.
FIELD: pharmaceutical industry. SUBSTANCE: invention relates to medicinal form of omeprazol and method of its making. Omeprazol-containing pellets are prepared using sucrose-containing internal core. Indicated core is covered with micronized active substance mixed with mannitol, lactose, sodium lauryl sulfate and sodium hydrogen phosphate that makes solid layer of preparation in applying. Then povidon-containing protective cover is applied. For making the final intestine-soluble cover hydroxypropylmethylcellulose phthalate, cetyl alcohol, acetone and isopropyl alcohol are applied. EFFECT: increased stability of omeprazol in medicinal form. 9 cl, 4 ex
Patients with renal insufficiency

TPOXX Injection: In healthy patients and in patients with mild to severe renal insufficiency, the majority of an 8 g dose of hydroxypropyl-β-cyclodextrin (per 200 mg tecovirimat/20 mL solution) is eliminated in the urine. It is known that clearance of hydroxypropyl-β-cyclodextrin is reduced in patients with mild, moderate, and severe renal impairment, resulting in higher exposure to hydroxypropyl-β-cyclodextrin; in these patients, half-life values are increased over normal values by approximately two-, four-, and six-fold, respectively. In these patients, successive infusions may result in accumulation of hydroxypropyl-β-cyclodextrin until steady state is reached.

In patients with mild (defined as creatinine clearance 60-89 mL/min) and moderate (defined as creatinine clearance 30-59 mL/min) renal impairment, TPOXX Injection should be used with caution. Creatinine clearance should be closely monitored and, if renal toxicity is suspected, consideration should be given to administering TPOXX orally if possible or to using an alternative medication. TPOXX Injection is contraindicated in patients with severe renal impairment (creatinine clearance 30 mL/min) [see Contraindictions (4) and Clinical Pharmacology (12.3)].

Pediatric patients

TPOXX Injection: In pediatric patients less than 2 years of age, there are limited data regarding the use of hydroxypropyl-β-cyclodextrin. Given that renal tubular function rapidly matures over the first few years of life, clearance of hydroxypropyl-β-cyclodextrin may be reduced in young pediatric patients, resulting in higher exposure to hydroxypropyl-β-cyclodextrin. TPOXX Injection should be used with caution in this population given that animal studies have shown potential for nephrotoxicity at very high exposure levels of hydroxypropyl-β-cyclodextrin. Given the potential for drug accumulation due to renal immaturity in pediatric patients less than 2 years, monitoring of renal function after treatment is recommended [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)].
Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
The invention discloses rose essential oil eye repairing and tightening essence and a preparation method thereof. Belongs to the technical field of cosmetics. The composite material comprises the following components in percentage by mass: 3-5% of rose essential oil, 20-35% of rose hydrosol, 5-6% of a humectant, 1.5-2% of a whitening component, 0.1-0.2% of a soothing and anti-allergy component, 1.5-2% of a natural antioxidant, 0.15-0.2% of a natural preservative, 0.4-0.6% of a natural emulsifier and the balance of deionized water. The invention takes rose essential oil and rose hydrosol as effective components, and adds a plurality of natural components and other components which promote permeation and absorption to interact with the effective components to prepare the eye-repairing and tightening essence. Easy absorption, safety and no irritation. The product has effects of moistening, tightening and smoothing eye skin, and can also relieve black eye, pouch, crow's feet, and fat granules.
Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
PURPOSE:To purify various proteins, rapidly, easily, in high yield, at a low cost, by using a cartridge-type adsorbent produced by filling the space in a cellulose mesh with an adsorption carrier, and filling the obtained sheet in a container. CONSTITUTION:The spaces of a cellulose mesh is filled with an adsorption carrier (e.g. an ion exchange resin), and the obtained sheet is filled preferably in the form of spiral in a container. Proteins (e.g. urokinase, kallikrein, lysozyme, blood coagulation factor, albumin, etc.) are purified by using the obtained cartridge- type adsorbent. A large amount of proteins can be purified in a short time, and the recovery reaches >=90%. Since the solution can be passed through the cartridge-type adsorbent at a high speed, it is especially useful when used in the treatment of a large amount of specimen such as the recovery of urokinase, kallikrein, etc. existing very little in urine.
BACKGROUND: SARS-CoV-2 reinfection rates have been shown to vary depending on the circulating variant, vaccination status and background immunity, as well as the time interval used to identify reinfections. This study describes the frequency of SARS-CoV-2 reinfections in Norway using different time intervals and assesses potential factors that could impact the risk of reinfections during the different variant waves.
METHODS: We used linked individual-level data from national registries to conduct a retrospective cohort study including all cases with a positive test for SARS-CoV-2 from February 2020 to January 2022. Time intervals of 30, 60, 90 or 180 days between positive tests were used to define potential reinfections. A multivariable Cox regression model was used to assess the risk of reinfection in terms of variants adjusting for vaccination status, demographic factors, and underlying comorbidities.
RESULTS: The reinfection rate varied between 0.2%, 0.6% and 5.9% during the Alpha, Delta and early Omicron waves, respectively. In the multivariable model, younger age groups were associated with a higher risk of reinfection compared to older age groups, whereas vaccination was associated with protection against reinfection. Moreover, the risk of reinfection followed a pattern similar to risk of first infection. Individuals infected early in the pandemic had higher risk of reinfection than individuals infected in more recent waves.
CONCLUSIONS: Reinfections increased markedly during the Omicron wave. Younger individuals, and primary infections during earlier waves were associated with an increased reinfection risk compared to primary infections during more recent waves, whereas vaccination was a protective factor. Our results highlight the importance of age and post infection waning immunity and are relevant when evaluating vaccination polices.
This invention relates to Id knockout mammals having a disruption in at least one and at most three alleles of inhibitor of differentiation genes, Id1 and Id3. This results in reduction or prevention of a cell proliferative disorder in the mammal as compared to a wild-type mammal. In particular, tumor growth and/or metastasis is shown to be inhibited. Further, tumor growth is shown to have poor vascularization and extensive necrosis in Id knockout mammals lacking 3 out of 4 of the Id1,Id3 alleles (Id1-/-Id3+/-). Drug screening methods to select agents useful to affect activity or expression of Id1, or Id3 gene products are disclosed. Therapeutic methods employing selected agents in subjects in need of treatment and diagnostic methods and test kits to identify subjects having, or at risk of having a neurological or cell proliferative disorder are also described.
Cold-inducible RNA-binding protein (CIRBP) and RNA binding motif protein 3 (RBM3) are both members of the cold shock protein family expressed in response to low-temperature induction. However, their usefulness in the diagnosis of fatal hypothermia in forensic has not been reported. In this study, we report the case of a female who died of fatal hypothermia. Through detailed case investigation, scene examination, autopsy testing and tissue observation, we ultimately determined that the woman died of hypothermia. We further examined the expression of CIRBP and RBM3 in the postmortem brain, heart, lung and kidney via immunohistochemistry. The high expression of CIRBP and RBM3 in the brain, lungs, and kidneys suggested the possibility of hypothermia. This study may provide new auxiliary diagnostic indicators for the diagnosis of fatal hypothermia in forensic medicine.
PURPOSE: To prepare a nanoemulsion of oil particles of >=200 nm in an aq. phase by compounding an aq. phase, oil and a specific amt. of an amorphous emulsifier having a thin-layer liquid crystal structure in the aq. phase and treating the same by a high-pressure homogenizer. CONSTITUTION: The nanoemulsion of the oil particles of <=200 nm from triglyceride or fatty acid ester is prepad. by compounding and mixing the aq. phase, the oil and 0.05 to 0.4 pt.wt. an amorphous emulsifier having a thin layer liquid crystal structure in the aq. phase (per pt.wt. of the oil), then subjecting the mixture to an agitating treatment in the high-pressure homogenizer. The emulsifier is adequately the glycerophosphatide expressed by formula I (R1 and R2 denote acyloxy, alkyl or alkenyl ether, R3 denotes tri-lower-alkyl ammonio or amino substd. lower alkyl). The total concn. of the oil in the aq. phase and the emulsifier is adequately <=20 wt.%.
The invention disclosed a freeze-dried nanometer powder injection of ursolic acid. It major compose of active material of ursolic acid, complex vehicle of nanometer powder, excipient of freeze-drying. Compare to other popular preparations, its advantages are high target application of liver, concentrate on the affects, increase curative effect, decrease side effect, high dispersity and stability. It is prepared through dissolving ursolic acid as active raw material in medical organic solvent, adding complex vehicle of bean lecithin and stearic acid, stirring while heating until reaction completed, adding distilled water, adding excipient, stirring while heating until reaction completed, filtering with microporous membrane and freeze-drying the filtrate. Its average particle size is 209.5 nm, comprise of 25.2% drug. It is for inhibiting and treating liver cancer, decreasing expression of p53, bcl-2 and topo-II.
FIELD: medicine, immunology, polymers. SUBSTANCE: invention relates to hydrogel that presents copolymer of N-substituted methacrylamide or acrylamide, cross-linking agent and sugar compound or its derivative, tissue-binding peptide or polymer coupled with antibodies. Polymer is presented by heterogeneous elastic-deformation structure with equilibrium water content, at least, about 80%. It can be used for tissue regeneration and organ recovery, for example, in developing and mature nervous system. Hydrogel shows the improved ability for tissue healing in the process of tissue formation that is achieved owing to control over cells proliferation, cells infiltration and tissue organization in stable polymeric matrix. EFFECT: improved method of preparing, valuable medicinal properties. 18 cl, 4 dwg
The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. Treatment will be at 100% of MT. Treatment will be approximately 2 ½ minutes long. Each session will be 2-hours in length and consist of four treatments spaced 30 minutes apart. There will be a total of five sessions over the course of five to seven days.
PURPOSE: To assess the visual and clinical outcomes after bilateral implantation of the novel extended depth of focus (EDOF) (AcrySof IQ Vivity) intraocular lens (IOL) using a micromonovision strategy.
METHODS: This was a prospective interventional study at a tertiary care center. Twenty patients (40 eyes) underwent bilateral implantation of AcrySof IQ Vivity IOL. Twelve weeks postoperatively, both uncorrected vision and corrected vision were assessed. Uniocular and binocular defocus curves with and without correction were noted subjectively as well as objectively on I-trace. Contrast sensitivity was assessed with a FACT (Functional Acuity Contrast Testing) machine, and objective parameters like modulation transfer function and Strehl ratio were also measured on I-Trace. Subjective quality of vision using a subjective questionnaire was also evaluated.
RESULTS: The mean binocular postoperative uncorrected distance visual acuity in LogMAR was -0.03 ± 0.09, the uncorrected intermediate visual acuity was 0.03 ± 0.09, and the uncorrected near visual acuity was 0.28 ± 0.18. All defocus curves were smooth and broad with the uncorrected defocus curve (with the micromonovision strategy) better than the corrected defocus curve. The subjective depth of focus (DOF = 3.73) was more than objective DOF (1.93) (P < 0.05). Photopic contrast was better than mesopic at all frequencies. All aberrations increased at 5 mm pupil size compared to 3 mm pupil size and were statistically significant, except for the total eye spherical aberration, which shows no significant difference at 3 mm and 5 mm pupil size (P = 0.27). Spectacle independence for distance, intermediate, and near was achieved in 100%, 94.7%, and 94.7% cases in this study, respectively.
CONCLUSIONS: Using the micromonovision strategy, the visual performance of this novel EDOF IOL was outstanding both subjectively and objectively.
Effervescent granules, or granules compressible into tablets are mred by mixing an acid powder, (pref. citric acid) and a base powder, (pref. NaHCO3), each separately with a little water. The two pastes are then mixed; a limited reaction occurs, and granules form without the need for a granulator and calibrator. Method is cheap and convenient. The granule may subsequently the compressed with active ingredients and excipients into tablets.
INTRODUCTION: Non-pancreatic pseudocysts are rare lesions that typically form from the omentum and mesentery. These cysts have a thick fibrotic wall made up of fibrous tissue and may show signs of calcifications and inflammatory changes. The fluid inside them can vary, ranging from hemorrhage and pus to serous or sometimes chylous content. In most cases, these cysts appear as a result of trauma, surgery, or infection.
CASE PRESENTATION: A 35-year-old male patient from Ethiopia presented with swelling in his lower abdomen that had been present for 2 years. Initially, the swelling was small but gradually increased in size. The patient experienced frequent urination but no pain or difficulty during urination, urgency, intermittent urination, or blood in the urine. The swelling was initially painless but became painful 2 months prior to his presentation. Abdominal computed tomography scans revealed a well-defined, lobulated peritoneal lesion measuring 16 × 12 × 10 cm, consisting primarily of fluid-filled cysts with a thick, enhancing wall and septa. Additionally, there was a large, heterogeneous enhancing soft tissue component measuring 8 × 6 cm. As a result, the cystic mass was surgically removed in its entirety with partial removal of the bladder wall, and the patient was discharged in an improved condition.
CONCLUSION: Primary non-pancreatic pseudocysts are extremely rare lesions that must be differentiated from other possible causes of cystic lesions within the peritoneal or retroperitoneal regions. Surgeons should be aware of the potential occurrence of these lesions, which may have an unknown origin.
PURPOSE:To obtain a compound useful as a cocaine-protein conjugate known as an immunogen for the preparation of anticocaine antibody. CONSTITUTION:The compound of formula I ((n) is integer of >=1). This compound can be produced by reacting norcocaine of formula II with bromobutylphthalimide in the presence of anhydrous sodium carbonate in benzene solvent. The norcocaine of formula II is obtained by dissolving cocaine in a mixed solvent (e.g. acetonitrile-water), adjusting the solution to a weakly acidic state by adding acetic acid, dropping potassium permanganate solution and reacting at room temperature. A pyridyldithio derivative of formula III having a functional group (disulfide group) capable of forming a bond with protein is easily synthesized while maintaining the principal skeleton of cocaine by using the compound of formula I. A cocaine-protein conjugate can be synthesized by bonding the compound of formula III to a protein through a disulfide bond.
A composition comprising an amphoteric surfactant, an alkoxylated cetyl alcohol and a polar drug, wherein the total amount of preservative present in the composition is 0.2%w/w or less. Preferably, if the preservative is present, it is not benzyl alcohol and/or triclosan, preferably the preservative is chlorocresol. The polar drug may be an anionic drug, most preferably sodium cromoglicate and/or nedocromil sodium. The amphoteric surfactant is preferably disodium cocoamphodiacetate. Preferably, the alkoxylated cetyl alcohol is polypropoxylated cetyl alcohol (worked examples comprise Procetyl AWS). The polar drug may also be a corticosteroid, antibacterial agent, antirheumatic agent, nicotine or a hormone. The composition is preferably an oil-in-water emulsion for topical administration. The composition is for use in medicine, preferably a skin disease involving mast cells and/or delayed hypersensitivity reactions and/or inflammation, for example, atopic dermatitis or eczema. The composition provides adequate skin penetration of the polar drug and provides a stable composition with low levels of preservatives.
The invention discloses a preparation method of eupolyphaga seu steleophagadry dry powder extract. The method adopted by the invention includes water extraction method or enzymolysis method. The eupolyphaga seu steleophagadry dry powder is firstly processed with water extraction or enzymolysis; the water extraction liquid or enzymolysis liquid is chromatographically separated through Sephadex G25 column to obtain the polypeptide component series, and then the polypeptide component is frozen and dried to prepare frozen dry powder. The model evaluation of mouse ear swelling indicates that the polypeptide component series of eupolyphaga seu steleophagadry dry powder extract has obvious inhibition effect on pain. The experiment of feeding mice for a month indicates that the polypeptide component has no toxicity and no dependence. The invention provides the application of polypeptide component series of eupolyphaga seu steleophagadry dry powder extract in the preparation of analgesic medicines.
Between 36 and 75% of oncologic patients experience anemia and anemia is associated with poor prognosis. Up to 40% of surgical oncologic patients receive red blood cells (RBC). However, transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality. This is a retrospective, single center study. All adults admitted to the intensive care unit (ICU) after oncologic surgery within the study period are eligible.
Potential subjects aged 5 years to 12 years, 11 months old with anorexia nervosa (AN) diagnosed with ARFID and their families will be recruited will be recruited through Stanford University, pediatricians, mental health experts, clinics treating EDs, and local parents' groups. Those eligible for the program will be invited to read and sign informed consent forms and complete the baseline assessment. They will then be randomized to the FBT-ARFID program either immediately after their screening or 3 months after assessment (i.e., to a usual care group). FBT-ARFID consists of 22 sessions over a 6-month period.

There will be 3 major assessment time points for those in the FBT-ARFID Arm: Baseline, 3 months into treatment, and EOT. There will be 4 major assessment time points for those in Usual Care: Baseline, transition to treatment (3 months after the usual care period is complete), 3 months into treatment, and EOT. Both the child and the parent will complete measures at these time points. In addition, patients and parents will participate in ongoing qualitative assessments before treatment (BL), throughout treatment (every other session), and at EOT.
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that is widely used for the treatment of peripheral vascular occlusive disorders. In addition, PTX has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria due to early and advanced diabetic nephropathy. However, data with respect to its effect on non-nephrotic primary glomerular diseases are lacking. Moreover, while the anti-proteinuric effect of PTX has been largely attributed to down-regulation of TNF-a, it remains unknown whether other mediators, especially MCP-1, are also affected by PTX. Because our previous works have shown that PTX attenuates proteinuria and suppresses renal MCP-1 mRNA expression in experimental glomerulonephritis in rats, we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis. This study was thereby conducted to investigate the potential anti-proteinuric and anti-MCP-1 effects of PTX in subnephrotic patients with primary glomerular diseases.
PURPOSE: To prepare a composition for use in a mouth, comprising a linear polymeric carboxylate polymer, a soluble strontium ion source and a soluble fluoride ion source and capable of making the uptake of the fluoride with an enamel of teeth more effective. CONSTITUTION: This composition for use in a mouth comprises (A) a polymer selected from a linear polymeric carboxylate (co)polymer, a sulfonate (co)polymer and a sulfate (co)polymer, (B) a soluble strontium ion source (e.g. a strontium salt or complex), (C) a soluble fluoride ion source, e.g. sodium fluoride or sodium monofluorophosphate) and (D) a carrier acceptable in the mouth without containing a linear uncross-linked acrylic acid (co)polymer. The amounts of the respective compounded ingredients are preferably within the following the ranges. About 0.0003-13%, preferably about 0.03-4% ingredient A, about 150-10,000ppm, preferably about 500-4,000ppm ingredient B expressed in terms of strontium ions and 0.0025-5.0%, preferably about 0.005-2.0% ingredient C.